Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxybutynin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aroxybutynin SCHEMBL25880 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL1560964 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Esoxybutynin SCHEMBL290373 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL7895841 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL8019436 | 0.99 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL25751 | 0.99 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL19816026 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL4606219 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL5494388 | 0.99 | MEN1 (1.00) | CHRM2CHRM1CHRM4CHRM3KCNH2 | |
| Oxybutynin SCHEMBL7557853 | 0.99 | CHRM2 (0.98) | CHRM2CHRM1CHRM4CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17440 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12638459-B2 | Method of diagnosing overactive bladder disorder | UNIVERSITY OF PORTSMOUTH HIGHER EDUCATION CORPORATION (GB) | 2026-05-26 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| EP-3659594-B2 | A STERILE SOLUTION WITH AN APPLICATION INJECTOR COMPRISING A MEDICAL AGENT AND METHOD FOR PRODUCING SAME | STEGEMANN KLAUS (DE) | 2026-04-29 | — | — | EP | claimed |
| EP-4222753-B1 | METHODS AND SYSTEMS FOR PERFORMING DOSE TITRATION | KONINKLIJKE PHILIPS NV (NL) | 2026-04-15 | — | — | EP | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-0700284-A1 | CONTROLLED RELEASE OXYBUTYNIN FORMULATIONS | EDWARD MENDELL CO., INC. (US) | 1996-03-13 | — | — | EP | claimed |
| CN-1111507-A | Controlled release oxybutynin formulations | MENDELL CO INC EDWARD (US) | 1995-11-15 | — | — | CN | claimed |
| WO-1995023593-A1 | CONTROLLED RELEASE OXYBUTYNIN FORMULATIONS | BAICHWAL ANAND (US) | 1995-09-08 | — | — | WO | claimed |
| US-5411740-A | Drug delivery | ALZA CORPORATION (US) | 1995-05-02 | — | — | US | claimed |
| WO-1995009007-A1 | MONOGLYCERIDE/LACTATE ESTER PERMEATION ENHANCER FOR OXYBUTYNIN | ALZA CORPORATION (US) | 1995-04-06 | — | — | WO | claimed |
| US-5399359-A | Antispasmodic | EDWARD MENDELL CO., INC. (US) | 1995-03-21 | — | — | US | claimed |
| WO-1993023025-A1 | TRANSDERMAL ADMINISTRATION OF OXYBUTYNIN | ALZA CORPORATION (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0250125-B1 | DRUG DELIVERY DEVICE, ITS PREPARATION AND USE | Smith & Nephew plc (GB) | 1991-09-18 | — | — | EP | claimed |
| US-4784857-A | Drug delivery device, its preparation and use | SMITH AND NEPHEW ASSOCIATED COMPANIES PLC (GB) | 1988-11-15 | — | — | US | claimed |
| EP-0250125-A2 | Drug delivery device, its preparation and use | Smith & Nephew plc (GB) | 1987-12-23 | — | — | EP | claimed |